stock price decline

Class action lawsuits filed against BlackRock TCP Capital and Plug Power for alleged material misrepresentations regarding financial information and business operations.

PayPal faces class action lawsuit alleging misleading revenue guidance. Stock dropped 20% after weak Q4 results and withdrawn 2027 guidance; CEO transition announced.

KDDI delayed earnings disclosure due to internal investigation, triggering 11.44% stock decline. Law firm investigating potential securities law violations.

Kyndryl faces securities fraud lawsuit over alleged misrepresentations. Stock plunged 55% after February disclosure of internal control weaknesses. Investors have until April 13 to join class action.

Class action lawsuit filed against PayPal for allegedly making false statements about 2027 financial targets and Branded Checkout expansion while concealing sales organization problems.

Law firm investigates Beta Bionics for potential securities fraud after stock plunged 37% due to slowing patient growth, missing investor expectations on guidance accuracy.

Law firm investigates Celestica for potential securities fraud after reports Google may shift TPU assembly work to other suppliers, raising disclosure concerns.

Pomerantz launches class action against Vistagen after failed clinical trial caused 80% stock drop. March 16, 2026 deadline for investors to join lawsuit.

Ralliant Corporation faces securities investigation over $1.4B impairment charge. Stock plunged 31.8%, raising questions about delayed disclosure of material information to investors.

Robbins LLP files class action suit against Agilon Health for allegedly issuing unachievable 2025 guidance and overstating strategic initiatives, following 50% stock decline.

Portnoy Law Firm files class action against Oracle for failing to timely disclose a $15 billion CapEx increase tied to its OpenAI partnership deal.

Kyndryl investors face April 13 deadline to become lead plaintiff in securities class action over financial reporting failures and misstatements.

Securities lawsuit against uniQure alleges misleading FDA disclosure statements about gene therapy candidate AMT-130. Stock fell 49% after November FDA feedback; investors must file claims by April 13, 2026.

GSI Technology faces securities investigation for allegedly making false claims about chip capabilities. Stock dropped 14.2% after reports showed products didn't perform as advertised.

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.

Law firm investigates Ardent Health for allegedly false financial disclosures. Stock fell 33.81% after company revealed $43M revenue cut, $54M liability increase. Investors have until March 9 to join class action.

Plug Power faces securities fraud lawsuit for allegedly misleading investors about a $1.66 billion DOE hydrogen funding program. Stock fell over 27% after CEO departure and loan suspension.

BRBR faces securities fraud lawsuit alleging misrepresented sales growth. Investors must file claims by March 23, 2026.

CoreWeave faces securities fraud lawsuit alleging false statements about operational capabilities and undisclosed data center project delays. Class action deadline: March 13, 2026.

Rosen Law Firm investigates PennyMac Financial for alleged disclosure issues after Q4 earnings triggered 33% stock decline on January 30, 2026.